GT Biopharma (GTBP) Reports Preclinical Data Demonstrating S

GT Biopharma (GTBP) Reports Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager Driving Robust NK Cell Function Against B Cell Malignancies

GT Biopharma (GTBP) Reports Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager Driving Robust NK Cell Function Against B Cell Malignancies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , American , Jeff Miller , Gregory Berk , Congress Poster Details , University Of Minnesota , European Hematology Association , Gt Biopharma Inc , American Cancer Society , Nasdaq , Wall Street , Tri Specific Killer Engager Drives Robust , Function Againstb Cell Malignancies , Chief Medical Officer , Function Againstb Cell , Poster Details , Session Date , Chronic Lymphocytic Leukemiachronic ,